News | December 03, 2013

International Study Finds Heart Disease Similar in Men, Women

Computed tomography scan of the heart, allowing 3-D views of cardiac anatomy, including the coronary arteries.


December 3, 2013 — An analysis of data from an international multicenter study of coronary computed tomography angiography (CCTA) reveals that men and women with mild coronary artery disease (CAD) and similar cardiovascular risk profiles share similar prognoses. Results of the study were presented at the Radiological Society of North America Annual Meeting (RSNA 2013).
 
"We conducted this study because we wanted to understand whether men and women with the same extent of coronary artery disease and similar risk profiles have similar or dissimilar prognoses," said Jonathon Leipsic, M.D., FRCPC, director of medical imaging, St. Paul's Hospital in Vancouver, British Columbia. "There is a tendency to think women's heart disease is very different than men's heart disease. Our data show that once plaque accumulates in the coronary arteries, the prognosis is very similar between men and women."
 
For the study, Leipsic and a team of researchers used data from the Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter (CONFIRM) Registry, which collected information on 27,725 individuals in six countries who underwent CCTA. The registry also included participants' traditional risk factors, allowing for the derivation of Framingham scores, which are used to determine an individual's risk of developing cardiovascular disease.
 
From the registry, the researchers identified 18,158 patients without known CAD whose CCTA results were normal or indicated nonobstructive disease, in which coronary arteries were less than 50 percent blocked. These patients, including 8,808 women and 9,350 men, were then matched on the basis of pre-existing cardiovascular risk factors and the extent of their CAD as determined by CCTA, resulting in a one-to-one cohort of 11,462 patients.
 
A statistical analysis of the matched cohort revealed that, controlling for all cardiovascular risk factors, nonobstructive CAD conferred a similar adverse risk of death or heart attack in both men and women. Conversely, the absence of plaque on CCTA conferred a good prognosis for both men and women. Of the patients in the cohort, only 251 experienced a heart attack or cardiac-related death during an average follow-up period of 2.3 years.
 
"This analysis is exciting, because this has never been shown before," said Leipsic. "There's a prevailing belief that mild CAD puts women at greater risk for a major cardiac event compared to men with mild CAD. Our findings show this is just not true."
 
For more information: www.rsna.org

Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now